MedPal AI (MPAL) has launched a new digital marketing campaign for its private weight management platform, New Health, as the company positions itself for anticipated growth in the UK GLP-1 market.
The AI-native digital health and pharmacy group said paid advertising has commenced across Meta and Google to support patient acquisition and increase brand awareness for new.co.uk. The campaign forms part of MedPal's previously announced investment programme for the platform.
The update comes as demand for GLP-1 weight management therapies continues to grow globally. MedPal highlighted recent data from Novo Nordisk showing that prescriptions for its oral semaglutide weight-loss treatment have exceeded 3 million in the United States since launching in January 2026. More than 80% of new prescriptions were from patients who had not previously used GLP-1 therapies, suggesting oral treatments are expanding the market rather than replacing injectable products.
Meanwhile, an oral formulation of semaglutide for weight management remains under review by the UK's Medicines and Healthcare products Regulatory Agency (MHRA), with a decision expected later in 2026.
MedPal said its NHS Distance Selling Pharmacy infrastructure, including automated dispensing facilities in Runcorn and Swaffham, provides a strong operational foundation to support future demand. The company believes the combination of this pharmacy network and the New Health clinical platform leaves it well placed to participate in the UK oral GLP-1 opportunity if regulatory approval is granted.
MedPal AI's Founder and Chief Executive Officer Jason Drummond said:
"The scale of patient demand for GLP-1 therapy is one of the defining healthcare trends of this decade, and the data emerging from the US oral launch underlines how much of that demand is coming from people new to the treatment. We are investing now to build new.co.uk into a recognised UK brand in weight management, so that MedPal is well positioned to serve patients across both injectable and, in due course and subject to regulatory approval, oral therapies. Our pharmacy dispensing infrastructure is a genuine differentiator as this market matures."
View from Vox
MedPal is moving early to build brand recognition in what could become one of the fastest-growing areas of private healthcare. While UK approval for oral GLP-1 treatments is still pending, the company is investing ahead of that potential catalyst and leveraging its existing pharmacy infrastructure to strengthen its position in a rapidly expanding market.